APO Research
Talk to an analyst

APO RESEARCH · REPORT

Remicade Biosimilar

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Remicade Biosimilar Market Outlook and Growth Opportunities 2026

19 December 2025191 pages

Choose your research edition.

Industry ResearchRemicade Biosimilar Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Remicade Biosimilar Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Remicade Biosimilar Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Remicade Biosimilar Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Remicade Biosimilar Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Remicade Biosimilar market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Remicade Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Remicade Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Remicade Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Remicade Biosimilar market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Remicade Biosimilar market include Walvax Biotechnology, Livzon Pharmaceutical, Hualan Biological Engineering, Hisun Pharmaceutical, Fosun Pharmaceutical, Anke Biotechnology, Synthon Pharmaceuticals, Novartis (Sandoz) and Merck Serono (Merck Group), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Remicade Biosimilar market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Remicade Biosimilar and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Remicade Biosimilar sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Remicade Biosimilar market size, projected growth trends, production technologies, key applications, and end-use industries.

Remicade Biosimilar Segment by Company

Walvax Biotechnology

Livzon Pharmaceutical

Hualan Biological Engineering

Hisun Pharmaceutical

Fosun Pharmaceutical

Anke Biotechnology

Synthon Pharmaceuticals

Novartis (Sandoz)

Merck Serono (Merck Group)

LG Life Sciences

Hospira

Genentech (Roche Group)

Celltrion

Biogen idec Inc.

Biocon

Remicade Biosimilar Segment by Type

100mg/10ml

500mg/50ml

Remicade Biosimilar Segment by Application

Blood Disorders

Oncology Diseases

Remicade Biosimilar Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Remicade Biosimilar status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Remicade Biosimilar market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Remicade Biosimilar significant trends, drivers, influence factors in global and regions.

6. To analyze Remicade Biosimilar competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Remicade Biosimilar market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Remicade Biosimilar and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Remicade Biosimilar.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Remicade Biosimilar market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Remicade Biosimilar industry.

Chapter 3: Detailed analysis of Remicade Biosimilar manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Remicade Biosimilar in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Remicade Biosimilar in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Remicade Biosimilar Industry Trends Table 2. Remicade Biosimilar Industry Drivers Table 3. Remicade Biosimilar Industry Opportunities and Challenges Table 4. Remicade Biosimilar Industry Restraints Table 5. Global Remicade Biosimilar Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Remicade Biosimilar Revenue Share by Company (2021-2026) Table 7. Global Remicade Biosimilar Sales Volume by Company (L) & (2021-2026) Table 8. Global Remicade Biosimilar Sales Volume Share by Company (2021-2026) Table 9. Global Remicade Biosimilar Average Price (US$/L) of Company (2021-2026) Table 10. Global Remicade Biosimilar Company Ranking, (2024-2026) & (USD Million) Table 11. Global Remicade Biosimilar Key Company Manufacturing Base & Headquarters Table 12. Global Remicade Biosimilar Company, Product Type & Application Table 13. Global Remicade Biosimilar Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Remicade Biosimilar by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 100mg/10ml Table 18. Significant Companies of 500mg/50ml Table 19. Global Remicade Biosimilar Sales Volume by Type 2021 VS 2025 VS 2032 (L) Table 20. Global Remicade Biosimilar Sales Volume by Type (2021-2026) & (L) Table 21. Global Remicade Biosimilar Sales Volume by Type (2027-2032) & (L) Table 22. Global Remicade Biosimilar Sales Volume Share by Type (2021-2026) Table 23. Global Remicade Biosimilar Sales Volume Share by Type (2027-2032) Table 24. Global Remicade Biosimilar Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Remicade Biosimilar Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Remicade Biosimilar Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Remicade Biosimilar Sales Value Share by Type (2021-2026) Table 28. Global Remicade Biosimilar Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Blood Disorders Table 30. Significant Companies of Oncology Diseases Table 31. Global Remicade Biosimilar Sales Volume by Application 2021 VS 2025 VS 2032 (L) Table 32. Global Remicade Biosimilar Sales Volume by Application (2021-2026) & (L) Table 33. Global Remicade Biosimilar Sales Volume by Application (2027-2032) & (L) Table 34. Global Remicade Biosimilar Sales Volume Share by Application (2021-2026) Table 35. Global Remicade Biosimilar Sales Volume Share by Application (2027-2032) Table 36. Global Remicade Biosimilar Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Remicade Biosimilar Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Remicade Biosimilar Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Remicade Biosimilar Sales Value Share by Application (2021-2026) Table 40. Global Remicade Biosimilar Sales Value Share by Application (2027-2032) Table 41. Global Remicade Biosimilar Sales by Region: 2021 VS 2025 VS 2032 (L) Table 42. Global Remicade Biosimilar Sales by Region (2021-2026) & (L) Table 43. Global Remicade Biosimilar Sales Market Share by Region (2021-2026) Table 44. Global Remicade Biosimilar Sales by Region (2027-2032) & (L) Table 45. Global Remicade Biosimilar Sales Market Share by Region (2027-2032) Table 46. Global Remicade Biosimilar Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Remicade Biosimilar Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Remicade Biosimilar Sales Value Share by Region (2021-2026) Table 49. Global Remicade Biosimilar Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Remicade Biosimilar Sales Value Share by Region (2027-2032) Table 51. Global Remicade Biosimilar Market Average Price (US$/L) by Region (2021-2026) Table 52. Global Remicade Biosimilar Market Average Price (US$/L) by Region (2027-2032) Table 53. Global Remicade Biosimilar Sales by Country: 2021 VS 2025 VS 2032 (L) Table 54. Global Remicade Biosimilar Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Remicade Biosimilar Sales by Country (2021-2026) & (L) Table 56. Global Remicade Biosimilar Sales Market Share by Country (2021-2026) Table 57. Global Remicade Biosimilar Sales by Country (2027-2032) & (L) Table 58. Global Remicade Biosimilar Sales Market Share by Country (2027-2032) Table 59. Global Remicade Biosimilar Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Remicade Biosimilar Sales Value Market Share by Country (2021-2026) Table 61. Global Remicade Biosimilar Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Remicade Biosimilar Sales Value Market Share by Country (2027-2032) Table 63. Walvax Biotechnology Company Information Table 64. Walvax Biotechnology Business Overview Table 65. Walvax Biotechnology Remicade Biosimilar Sales (L), Value (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 66. Walvax Biotechnology Remicade Biosimilar Product Portfolio Table 67. Walvax Biotechnology Recent Development Table 68. Livzon Pharmaceutical Company Information Table 69. Livzon Pharmaceutical Business Overview Table 70. Livzon Pharmaceutical Remicade Biosimilar Sales (L), Value (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 71. Livzon Pharmaceutical Remicade Biosimilar Product Portfolio Table 72. Livzon Pharmaceutical Recent Development Table 73. Hualan Biological Engineering Company Information Table 74. Hualan Biological Engineering Business Overview Table 75. Hualan Biological Engineering Remicade Biosimilar Sales (L), Value (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 76. Hualan Biological Engineering Remicade Biosimilar Product Portfolio Table 77. Hualan Biological Engineering Recent Development Table 78. Hisun Pharmaceutical Company Information Table 79. Hisun Pharmaceutical Business Overview Table 80. Hisun Pharmaceutical Remicade Biosimilar Sales (L), Value (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 81. Hisun Pharmaceutical Remicade Biosimilar Product Portfolio Table 82. Hisun Pharmaceutical Recent Development Table 83. Fosun Pharmaceutical Company Information Table 84. Fosun Pharmaceutical Business Overview Table 85. Fosun Pharmaceutical Remicade Biosimilar Sales (L), Value (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 86. Fosun Pharmaceutical Remicade Biosimilar Product Portfolio Table 87. Fosun Pharmaceutical Recent Development Table 88. Anke Biotechnology Company Information Table 89. Anke Biotechnology Business Overview Table 90. Anke Biotechnology Remicade Biosimilar Sales (L), Value (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 91. Anke Biotechnology Remicade Biosimilar Product Portfolio Table 92. Anke Biotechnology Recent Development Table 93. Synthon Pharmaceuticals Company Information Table 94. Synthon Pharmaceuticals Business Overview Table 95. Synthon Pharmaceuticals Remicade Biosimilar Sales (L), Value (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 96. Synthon Pharmaceuticals Remicade Biosimilar Product Portfolio Table 97. Synthon Pharmaceuticals Recent Development Table 98. Novartis (Sandoz) Company Information Table 99. Novartis (Sandoz) Business Overview Table 100. Novartis (Sandoz) Remicade Biosimilar Sales (L), Value (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 101. Novartis (Sandoz) Remicade Biosimilar Product Portfolio Table 102. Novartis (Sandoz) Recent Development Table 103. Merck Serono (Merck Group) Company Information Table 104. Merck Serono (Merck Group) Business Overview Table 105. Merck Serono (Merck Group) Remicade Biosimilar Sales (L), Value (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 106. Merck Serono (Merck Group) Remicade Biosimilar Product Portfolio Table 107. Merck Serono (Merck Group) Recent Development Table 108. LG Life Sciences Company Information Table 109. LG Life Sciences Business Overview Table 110. LG Life Sciences Remicade Biosimilar Sales (L), Value (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 111. LG Life Sciences Remicade Biosimilar Product Portfolio Table 112. LG Life Sciences Recent Development Table 113. Hospira Company Information Table 114. Hospira Business Overview Table 115. Hospira Remicade Biosimilar Sales (L), Value (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 116. Hospira Remicade Biosimilar Product Portfolio Table 117. Hospira Recent Development Table 118. Genentech (Roche Group) Company Information Table 119. Genentech (Roche Group) Business Overview Table 120. Genentech (Roche Group) Remicade Biosimilar Sales (L), Value (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 121. Genentech (Roche Group) Remicade Biosimilar Product Portfolio Table 122. Genentech (Roche Group) Recent Development Table 123. Celltrion Company Information Table 124. Celltrion Business Overview Table 125. Celltrion Remicade Biosimilar Sales (L), Value (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 126. Celltrion Remicade Biosimilar Product Portfolio Table 127. Celltrion Recent Development Table 128. Biogen idec Inc. Company Information Table 129. Biogen idec Inc. Business Overview Table 130. Biogen idec Inc. Remicade Biosimilar Sales (L), Value (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 131. Biogen idec Inc. Remicade Biosimilar Product Portfolio Table 132. Biogen idec Inc. Recent Development Table 133. Biocon Company Information Table 134. Biocon Business Overview Table 135. Biocon Remicade Biosimilar Sales (L), Value (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 136. Biocon Remicade Biosimilar Product Portfolio Table 137. Biocon Recent Development Table 138. Key Raw Materials Table 139. Raw Materials Key Suppliers Table 140. Remicade Biosimilar Distributors List Table 141. Remicade Biosimilar Customers List Table 142. Research Programs/Design for This Report Table 143. Authors List of This Report Table 144. Secondary Sources Table 145. Primary Sources List of Figures Figure 1. Remicade Biosimilar Product Image Figure 2. Global Remicade Biosimilar Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Remicade Biosimilar Sales Value (2021-2032) & (US$ Million) Figure 4. Global Remicade Biosimilar Sales (2021-2032) & (L) Figure 5. Global Remicade Biosimilar Sales Average Price (US$/L) & (2021-2032) Figure 6. Global Remicade Biosimilar Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 100mg/10ml Image Figure 10. 500mg/50ml Image Figure 11. Global Remicade Biosimilar Sales Volume by Type (2021 VS 2025 VS 2032) & (L) Figure 12. Global Remicade Biosimilar Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Remicade Biosimilar Sales Volume Share by Type (2021-2032) Figure 14. Global Remicade Biosimilar Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Remicade Biosimilar Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Remicade Biosimilar Sales Value Share by Type (2021-2032) Figure 17. Blood Disorders Image Figure 18. Oncology Diseases Image Figure 19. Global Remicade Biosimilar Sales Volume by Application (2021 VS 2025 VS 2032) & (L) Figure 20. Global Remicade Biosimilar Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Remicade Biosimilar Sales Volume Share by Application (2021-2032) Figure 22. Global Remicade Biosimilar Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Remicade Biosimilar Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Remicade Biosimilar Sales Value Share by Application (2021-2032) Figure 25. Global Remicade Biosimilar Sales by Region: 2021 VS 2025 VS 2032 (L) Figure 26. Global Remicade Biosimilar Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Remicade Biosimilar Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Remicade Biosimilar Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Remicade Biosimilar Sales Value (2021-2032) & (US$ Million) Figure 30. North America Remicade Biosimilar Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Remicade Biosimilar Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Remicade Biosimilar Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Remicade Biosimilar Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Remicade Biosimilar Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Remicade Biosimilar Sales Value (2021-2032) & (US$ Million) Figure 36. South America Remicade Biosimilar Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Remicade Biosimilar Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Remicade Biosimilar Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Remicade Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Remicade Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Remicade Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Remicade Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Remicade Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Remicade Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Remicade Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Remicade Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Remicade Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Remicade Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Remicade Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Remicade Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Remicade Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Remicade Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Remicade Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Remicade Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Remicade Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Remicade Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Remicade Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Remicade Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Remicade Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Remicade Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Remicade Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Remicade Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Remicade Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Remicade Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Remicade Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Remicade Biosimilar Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Remicade Biosimilar Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Remicade Biosimilar Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • 100mg/10ml
  • 500mg/50ml
Applications
  • Blood Disorders
  • Oncology Diseases
Companies covered
  • Walvax Biotechnology
  • Livzon Pharmaceutical
  • Hualan Biological Engineering
  • Hisun Pharmaceutical
  • Fosun Pharmaceutical
  • Anke Biotechnology
  • Synthon Pharmaceuticals
  • Novartis (Sandoz)
  • Merck Serono (Merck Group)
  • LG Life Sciences
  • Hospira
  • Genentech (Roche Group)
  • Celltrion
  • Biogen idec Inc.
  • Biocon

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Remicade Biosimilar Sales Value (2021-2032)
  4. 1.2.2 Global Remicade Biosimilar Sales Volume (2021-2032)
  5. 1.2.3 Global Remicade Biosimilar Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Remicade Biosimilar Market Dynamics
  1. 2.1 Remicade Biosimilar Industry Trends
  2. 2.2 Remicade Biosimilar Industry Drivers
  3. 2.3 Remicade Biosimilar Industry Opportunities and Challenges
  4. 2.4 Remicade Biosimilar Industry Restraints
3 Remicade Biosimilar Market by Company
  1. 3.1 Global Remicade Biosimilar Company Revenue Ranking in 2025
  2. 3.2 Global Remicade Biosimilar Revenue by Company (2021-2026)
  3. 3.3 Global Remicade Biosimilar Sales Volume by Company (2021-2026)
  4. 3.4 Global Remicade Biosimilar Average Price by Company (2021-2026)
  5. 3.5 Global Remicade Biosimilar Company Ranking (2024-2026)
  6. 3.6 Global Remicade Biosimilar Company Manufacturing Base and Headquarters
  7. 3.7 Global Remicade Biosimilar Company Product Type and Application
  8. 3.8 Global Remicade Biosimilar Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Remicade Biosimilar Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Remicade Biosimilar Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Remicade Biosimilar Market by Type
  1. 4.1 Remicade Biosimilar Type Introduction
  2. 4.1.1 100mg/10ml
  3. 4.1.2 500mg/50ml
  4. 4.2 Global Remicade Biosimilar Sales Volume by Type
  5. 4.2.1 Global Remicade Biosimilar Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Remicade Biosimilar Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Remicade Biosimilar Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Remicade Biosimilar Sales Value by Type
  9. 4.3.1 Global Remicade Biosimilar Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Remicade Biosimilar Sales Value by Type (2021-2032)
  11. 4.3.3 Global Remicade Biosimilar Sales Value Share by Type (2021-2032)
5 Remicade Biosimilar Market by Application
  1. 5.1 Remicade Biosimilar Application Introduction
  2. 5.1.1 Blood Disorders
  3. 5.1.2 Oncology Diseases
  4. 5.2 Global Remicade Biosimilar Sales Volume by Application
  5. 5.2.1 Global Remicade Biosimilar Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Remicade Biosimilar Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Remicade Biosimilar Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Remicade Biosimilar Sales Value by Application
  9. 5.3.1 Global Remicade Biosimilar Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Remicade Biosimilar Sales Value by Application (2021-2032)
  11. 5.3.3 Global Remicade Biosimilar Sales Value Share by Application (2021-2032)
6 Remicade Biosimilar Regional Sales and Value Analysis
  1. 6.1 Global Remicade Biosimilar Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Remicade Biosimilar Sales by Region (2021-2032)
  3. 6.2.1 Global Remicade Biosimilar Sales by Region: 2021-2026
  4. 6.2.2 Global Remicade Biosimilar Sales by Region (2027-2032)
  5. 6.3 Global Remicade Biosimilar Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Remicade Biosimilar Sales Value by Region (2021-2032)
  7. 6.4.1 Global Remicade Biosimilar Sales Value by Region: 2021-2026
  8. 6.4.2 Global Remicade Biosimilar Sales Value by Region (2027-2032)
  9. 6.5 Global Remicade Biosimilar Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Remicade Biosimilar Sales Value (2021-2032)
  12. 6.6.2 North America Remicade Biosimilar Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Remicade Biosimilar Sales Value (2021-2032)
  15. 6.7.2 Europe Remicade Biosimilar Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Remicade Biosimilar Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Remicade Biosimilar Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Remicade Biosimilar Sales Value (2021-2032)
  21. 6.9.2 South America Remicade Biosimilar Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Remicade Biosimilar Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Remicade Biosimilar Sales Value Share by Country, 2025 VS 2032
7 Remicade Biosimilar Country-level Sales and Value Analysis
  1. 7.1 Global Remicade Biosimilar Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Remicade Biosimilar Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Remicade Biosimilar Sales by Country (2021-2032)
  4. 7.3.1 Global Remicade Biosimilar Sales by Country (2021-2026)
  5. 7.3.2 Global Remicade Biosimilar Sales by Country (2027-2032)
  6. 7.4 Global Remicade Biosimilar Sales Value by Country (2021-2032)
  7. 7.4.1 Global Remicade Biosimilar Sales Value by Country (2021-2026)
  8. 7.4.2 Global Remicade Biosimilar Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Remicade Biosimilar Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Remicade Biosimilar Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Remicade Biosimilar Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Remicade Biosimilar Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Remicade Biosimilar Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Remicade Biosimilar Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Remicade Biosimilar Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Remicade Biosimilar Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Remicade Biosimilar Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Remicade Biosimilar Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Remicade Biosimilar Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Remicade Biosimilar Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Remicade Biosimilar Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Remicade Biosimilar Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Remicade Biosimilar Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Remicade Biosimilar Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Remicade Biosimilar Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Remicade Biosimilar Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Remicade Biosimilar Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Remicade Biosimilar Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Remicade Biosimilar Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Remicade Biosimilar Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Remicade Biosimilar Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Remicade Biosimilar Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Remicade Biosimilar Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Remicade Biosimilar Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Remicade Biosimilar Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Remicade Biosimilar Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Remicade Biosimilar Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Remicade Biosimilar Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Walvax Biotechnology
  2. 8.1.1 Walvax Biotechnology Company Information
  3. 8.1.2 Walvax Biotechnology Business Overview
  4. 8.1.3 Walvax Biotechnology Remicade Biosimilar Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Walvax Biotechnology Remicade Biosimilar Product Portfolio
  6. 8.1.5 Walvax Biotechnology Recent Developments
  7. 8.2 Livzon Pharmaceutical
  8. 8.2.1 Livzon Pharmaceutical Company Information
  9. 8.2.2 Livzon Pharmaceutical Business Overview
  10. 8.2.3 Livzon Pharmaceutical Remicade Biosimilar Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Livzon Pharmaceutical Remicade Biosimilar Product Portfolio
  12. 8.2.5 Livzon Pharmaceutical Recent Developments
  13. 8.3 Hualan Biological Engineering
  14. 8.3.1 Hualan Biological Engineering Company Information
  15. 8.3.2 Hualan Biological Engineering Business Overview
  16. 8.3.3 Hualan Biological Engineering Remicade Biosimilar Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Hualan Biological Engineering Remicade Biosimilar Product Portfolio
  18. 8.3.5 Hualan Biological Engineering Recent Developments
  19. 8.4 Hisun Pharmaceutical
  20. 8.4.1 Hisun Pharmaceutical Company Information
  21. 8.4.2 Hisun Pharmaceutical Business Overview
  22. 8.4.3 Hisun Pharmaceutical Remicade Biosimilar Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Hisun Pharmaceutical Remicade Biosimilar Product Portfolio
  24. 8.4.5 Hisun Pharmaceutical Recent Developments
  25. 8.5 Fosun Pharmaceutical
  26. 8.5.1 Fosun Pharmaceutical Company Information
  27. 8.5.2 Fosun Pharmaceutical Business Overview
  28. 8.5.3 Fosun Pharmaceutical Remicade Biosimilar Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Fosun Pharmaceutical Remicade Biosimilar Product Portfolio
  30. 8.5.5 Fosun Pharmaceutical Recent Developments
  31. 8.6 Anke Biotechnology
  32. 8.6.1 Anke Biotechnology Company Information
  33. 8.6.2 Anke Biotechnology Business Overview
  34. 8.6.3 Anke Biotechnology Remicade Biosimilar Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Anke Biotechnology Remicade Biosimilar Product Portfolio
  36. 8.6.5 Anke Biotechnology Recent Developments
  37. 8.7 Synthon Pharmaceuticals
  38. 8.7.1 Synthon Pharmaceuticals Company Information
  39. 8.7.2 Synthon Pharmaceuticals Business Overview
  40. 8.7.3 Synthon Pharmaceuticals Remicade Biosimilar Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Synthon Pharmaceuticals Remicade Biosimilar Product Portfolio
  42. 8.7.5 Synthon Pharmaceuticals Recent Developments
  43. 8.8 Novartis (Sandoz)
  44. 8.8.1 Novartis (Sandoz) Company Information
  45. 8.8.2 Novartis (Sandoz) Business Overview
  46. 8.8.3 Novartis (Sandoz) Remicade Biosimilar Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Novartis (Sandoz) Remicade Biosimilar Product Portfolio
  48. 8.8.5 Novartis (Sandoz) Recent Developments
  49. 8.9 Merck Serono (Merck Group)
  50. 8.9.1 Merck Serono (Merck Group) Company Information
  51. 8.9.2 Merck Serono (Merck Group) Business Overview
  52. 8.9.3 Merck Serono (Merck Group) Remicade Biosimilar Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Merck Serono (Merck Group) Remicade Biosimilar Product Portfolio
  54. 8.9.5 Merck Serono (Merck Group) Recent Developments
  55. 8.10 LG Life Sciences
  56. 8.10.1 LG Life Sciences Company Information
  57. 8.10.2 LG Life Sciences Business Overview
  58. 8.10.3 LG Life Sciences Remicade Biosimilar Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 LG Life Sciences Remicade Biosimilar Product Portfolio
  60. 8.10.5 LG Life Sciences Recent Developments
  61. 8.11 Hospira
  62. 8.11.1 Hospira Company Information
  63. 8.11.2 Hospira Business Overview
  64. 8.11.3 Hospira Remicade Biosimilar Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Hospira Remicade Biosimilar Product Portfolio
  66. 8.11.5 Hospira Recent Developments
  67. 8.12 Genentech (Roche Group)
  68. 8.12.1 Genentech (Roche Group) Company Information
  69. 8.12.2 Genentech (Roche Group) Business Overview
  70. 8.12.3 Genentech (Roche Group) Remicade Biosimilar Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Genentech (Roche Group) Remicade Biosimilar Product Portfolio
  72. 8.12.5 Genentech (Roche Group) Recent Developments
  73. 8.13 Celltrion
  74. 8.13.1 Celltrion Company Information
  75. 8.13.2 Celltrion Business Overview
  76. 8.13.3 Celltrion Remicade Biosimilar Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Celltrion Remicade Biosimilar Product Portfolio
  78. 8.13.5 Celltrion Recent Developments
  79. 8.14 Biogen idec Inc.
  80. 8.14.1 Biogen idec Inc. Company Information
  81. 8.14.2 Biogen idec Inc. Business Overview
  82. 8.14.3 Biogen idec Inc. Remicade Biosimilar Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Biogen idec Inc. Remicade Biosimilar Product Portfolio
  84. 8.14.5 Biogen idec Inc. Recent Developments
  85. 8.15 Biocon
  86. 8.15.1 Biocon Company Information
  87. 8.15.2 Biocon Business Overview
  88. 8.15.3 Biocon Remicade Biosimilar Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Biocon Remicade Biosimilar Product Portfolio
  90. 8.15.5 Biocon Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Remicade Biosimilar Value Chain Analysis
  2. 9.1.1 Remicade Biosimilar Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Remicade Biosimilar Sales Mode & Process
  6. 9.2 Remicade Biosimilar Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Remicade Biosimilar Distributors
  9. 9.2.3 Remicade Biosimilar Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst